MX2022013595A - Metodos de uso de moduladores del canal de calcio tipo t. - Google Patents
Metodos de uso de moduladores del canal de calcio tipo t.Info
- Publication number
- MX2022013595A MX2022013595A MX2022013595A MX2022013595A MX2022013595A MX 2022013595 A MX2022013595 A MX 2022013595A MX 2022013595 A MX2022013595 A MX 2022013595A MX 2022013595 A MX2022013595 A MX 2022013595A MX 2022013595 A MX2022013595 A MX 2022013595A
- Authority
- MX
- Mexico
- Prior art keywords
- calcium channel
- type calcium
- methods
- epilepsy
- channel modulators
- Prior art date
Links
- 102000003691 T-Type Calcium Channels Human genes 0.000 title abstract 3
- 108090000030 T-Type Calcium Channels Proteins 0.000 title abstract 3
- 206010010904 Convulsion Diseases 0.000 abstract 2
- 206010015037 epilepsy Diseases 0.000 abstract 2
- 208000024658 Epilepsy syndrome Diseases 0.000 abstract 1
- 208000002877 Epileptic Syndromes Diseases 0.000 abstract 1
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 229940123939 T-type calcium channel antagonist Drugs 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 208000028311 absence seizure Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000006517 essential tremor Diseases 0.000 abstract 1
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Transmitters (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017140P | 2020-04-29 | 2020-04-29 | |
| US202063050410P | 2020-07-10 | 2020-07-10 | |
| US202063082946P | 2020-09-24 | 2020-09-24 | |
| PCT/US2021/029539 WO2021222342A1 (en) | 2020-04-29 | 2021-04-28 | Methods of use of t-type calcium channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013595A true MX2022013595A (es) | 2023-01-24 |
Family
ID=78373913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013595A MX2022013595A (es) | 2020-04-29 | 2021-04-28 | Metodos de uso de moduladores del canal de calcio tipo t. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230165847A1 (https=) |
| EP (1) | EP4142764A4 (https=) |
| JP (1) | JP2023524039A (https=) |
| KR (1) | KR20230018384A (https=) |
| CN (1) | CN115776894A (https=) |
| AU (1) | AU2021263804A1 (https=) |
| BR (1) | BR112022021946A2 (https=) |
| CA (1) | CA3177277A1 (https=) |
| IL (1) | IL297642A (https=) |
| MX (1) | MX2022013595A (https=) |
| WO (1) | WO2021222342A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114340670B (zh) | 2019-07-11 | 2026-02-17 | 普拉克西斯精密药物股份有限公司 | T-型钙通道调节剂的制剂及其使用方法 |
| US20250170114A1 (en) * | 2022-02-03 | 2025-05-29 | Praxis Precision Medicines, Inc. | Methods of treatment using t-type calcium channel modulators |
| AU2023244348A1 (en) * | 2022-03-28 | 2024-10-10 | Praxis Precision Medicines, Inc. | Methods of using oligomeric compounds to treat scn2a-related disorders |
| EP4522271A4 (en) * | 2022-05-09 | 2026-04-29 | Praxis Prec Medicines Inc | Methods of use of t-type calcium channel modulators |
| EP4673219A1 (en) * | 2023-03-02 | 2026-01-07 | Praxis Precision Medicines, Inc. | Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide and methods of use thereof |
| AU2024229946A1 (en) * | 2023-03-02 | 2025-09-11 | Praxis Precision Medicines, Inc. | Crystalline salts of a t-type calcium channel modulator and methods of use thereof |
| WO2025188619A1 (en) * | 2024-03-04 | 2025-09-12 | Praxis Precision Medicines, Inc. | Methods of treating parkinson's disease with t-type calcium channel modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377968B2 (en) * | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| JP6957460B2 (ja) * | 2015-10-22 | 2021-11-02 | カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． | アンジェルマン症候群および関連する障害の処置方法 |
| WO2017083867A1 (en) * | 2015-11-12 | 2017-05-18 | Afasci, Inc. | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
| CN110072521B (zh) * | 2016-12-16 | 2022-11-29 | 爱杜西亚药品有限公司 | 包含t型钙通道阻断剂的药物组合 |
| WO2018118101A1 (en) * | 2016-12-21 | 2018-06-28 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| AU2018364659A1 (en) * | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| IL300798B2 (en) * | 2018-10-03 | 2025-09-01 | Cavion Inc | Treatment of skeletal tremor with (r)–2-(4–isopropylphenyl)–n-(1-(5-(2,2,2–trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| CN114340670B (zh) * | 2019-07-11 | 2026-02-17 | 普拉克西斯精密药物股份有限公司 | T-型钙通道调节剂的制剂及其使用方法 |
| EP4522271A4 (en) * | 2022-05-09 | 2026-04-29 | Praxis Prec Medicines Inc | Methods of use of t-type calcium channel modulators |
-
2021
- 2021-04-28 CN CN202180046763.8A patent/CN115776894A/zh active Pending
- 2021-04-28 EP EP21795254.8A patent/EP4142764A4/en active Pending
- 2021-04-28 KR KR1020227041859A patent/KR20230018384A/ko active Pending
- 2021-04-28 MX MX2022013595A patent/MX2022013595A/es unknown
- 2021-04-28 IL IL297642A patent/IL297642A/en unknown
- 2021-04-28 AU AU2021263804A patent/AU2021263804A1/en active Pending
- 2021-04-28 CA CA3177277A patent/CA3177277A1/en active Pending
- 2021-04-28 JP JP2022566066A patent/JP2023524039A/ja active Pending
- 2021-04-28 BR BR112022021946A patent/BR112022021946A2/pt unknown
- 2021-04-28 WO PCT/US2021/029539 patent/WO2021222342A1/en not_active Ceased
-
2022
- 2022-10-27 US US17/975,457 patent/US20230165847A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3177277A1 (en) | 2021-11-04 |
| IL297642A (en) | 2022-12-01 |
| WO2021222342A1 (en) | 2021-11-04 |
| EP4142764A4 (en) | 2024-05-29 |
| BR112022021946A2 (pt) | 2023-01-17 |
| CN115776894A (zh) | 2023-03-10 |
| EP4142764A1 (en) | 2023-03-08 |
| KR20230018384A (ko) | 2023-02-07 |
| AU2021263804A1 (en) | 2023-01-19 |
| US20230165847A1 (en) | 2023-06-01 |
| JP2023524039A (ja) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013595A (es) | Metodos de uso de moduladores del canal de calcio tipo t. | |
| BR112022000429A2 (pt) | Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos | |
| MX2025001282A (es) | Moduladores de los canales ionicos | |
| WO2021252538A3 (en) | Advantageous benzofuran compositions for mental disorders or enhancement | |
| MX2021003634A (es) | Moduladores de canales de iones. | |
| MX2022006317A (es) | Moduladores de canales iónicos. | |
| WO2020163823A3 (en) | Therapeutic agents and methods of treatment | |
| EP4671248A3 (en) | Formulations of ion channel modulators and methods of preparation and use of ion channel modulators | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| MX2025005941A (es) | Moduladores de la actividad tnf-\03b1 | |
| MX383833B (es) | Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos. | |
| PH12021550176A1 (en) | Method for treating epilepsy | |
| MX2022011518A (es) | Metodos para tratar deambulacion asociada a proteinopatia. | |
| BR112022003959A2 (pt) | Métodos para tratamento de epilepsia | |
| MX2023008589A (es) | Compuestos moduladores de gcn2 y usos de los mismos. | |
| MX2022011041A (es) | Tratamiento de dolor y vasoconstriccion. | |
| MX2023012834A (es) | Inhibidor de la matriptasa-2 para el tratamiento de trastornos mieloproliferativos. | |
| MX2021003661A (es) | Moduladores de la monoacilglicerol lipasa. | |
| MX2024001590A (es) | Cianopiridina y degradadores de cianopirimidina bcl6. | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder | |
| MX2025008009A (es) | Moduladores de la proteolisis de bcl6 y metodos de uso asociados | |
| WO2025188619A8 (en) | Methods of treating parkinson's disease with t-type calcium channel modulators | |
| WO2021157939A3 (ko) | Saha를 유효성분으로 포함하는 뇌질환 예방 또는 치료용 조성물 | |
| MX2024007227A (es) | Psilocibina y un inhibidor de la recaptación de serotonina complementario para usar en el tratamiento de la depresión resistente al tratamiento. | |
| MX2022011888A (es) | Tratamiento de trastornos respiratorios. |